Geptanolimab

DB16417InvestigationalProtein Based Therapies

Geptanolimab is under investigation in clinical trial NCT03502629 (Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)).

Mechanism: Pharmacologically active on Programmed cell death protein 1
Curator reviewed
Also known as: Genolimzumab
Code names: APL-501 · CBT-501 · GB-226

Resolves to

Compound

UNIIFME52R2SGNCAS2348469-43-0

Targets

Q15116PDCD1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Geptanolimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account